AVTR · CIK 1722482
What Avantor, Inc. told the SEC could break it.
1 self-disclosed vulnerability, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for AVTR. More may follow as additional filings are processed.
In its own words
What could break it.
Sole-source dependency
- sole-sourced raw materials (APIs, excipients, components, compounds)medium
Avantor depends on high-quality raw materials — active pharmaceutical ingredients, components, compounds, excipients and others — many of which are sole-sourced due to market or customer demands; it has already experienced supply-chain constraints in sourcing certain products and raw materials.
“Our operations depend upon our ability to obtain high-quality raw materials meeting our specifications and other requirements at reasonable prices, including various active pharmaceutical ingredients, components, compounds, excipients and other raw materials, many of which are sole-sourced due to market or customer demands.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“we do not have guaranteed supply agreements with Thermo Fisher, Becton, Dickinson and Company or Avantor, which exposes us to the risk that these suppliers may choose to discontinue doing business with us at any time.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch